Impact of Obesity on the Efficacy of Endocrine Therapy With Aromatase Inhibitors

• Status: Recruiting
• Trial end date: 2020-06-01
• Target enrollment: 0
• Participant gender: Female

Summary

To see the impact of obesity on the efficacy of adjuvant endocrine therapy with aromatase inhibitors in postmenopausal patients with early breast cancer in terms of:

i) Locoregional recurrence ii) Distant metastases iii) Disease-free survival iv) Overall survival

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Postgraduate Institute of Medical Education and Research
• Treatments: Aromatase Inhibitors; Letrozole; Tamoxifen

Criteria

Inclusion Criteria:

• postmenopausal patients with breast cancer who have hormones receptor positive tumour as defined by the expression of oestrogen receptor (ER) and/or progesterone receptor (PR).

• patients with a tumour stage IB, IC, or II irrespective of nodal stage (< 10 positive nodes)

Exclusion Criteria:

• premenopausal patients,

• ER/PR negative